Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Inclusion Criteria: Histologically confirmed hematologic malignancy of 1 of the following histologies: Chronic lymphocytic leukemia (CLL) Small lymphocytic lymphoma (SLL) Noncontiguous stage II or stage III or IV disease Received >= 1 form of prior immunotherapy or chemotherapy Completed therapy at least 4 weeks ago Requires therapy (unless early bone marrow transplantation is planned), as indicated by 1 of the following criteria: Progressively worsening disease (symptoms increasing in severity by 1 toxicity criterion over a period of >= 2 weeks) Progressively worsening anemia or thrombocytopenia Progressively worsening lymphadenopathy Massive splenomegaly or hypersplenism Hyperlymphocytosis (WBC > 200,000/mm^3) OR lymphocyte doubling time < 12 months Marrow failure due to marrow infiltration by leukemia or lymphoma Leukemia cells must express 1D10 antigen > 2 times mean fluorescent intensity of the control by flow cytometry of blood or bone marrow cells Performance status - ECOG 0-2 At least 2 years Platelet count >= 50,000/mm^3 (transfusion independent) Bilirubin =< 3 mg/dL (unless due to tumor involvement) Creatinine =< 2.0 mg/dL No decompensated congestive heart failure No unstable angina No myocardial infarction within the past 6 months not corrected by surgery or percutaneous transluminal coronary angioplasty No active infection requiring oral or IV antibiotics No other malignancy that limits life expectancy to < 2 years or that requires active anticancer therapy within 4 weeks of study entry HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for at least 3 months after study treatment Recovered from prior immunotherapy More than 3 months since prior alemtuzumab or rituximab No prior apolizumab Recovered from prior chemotherapy More than 4 weeks since prior anticancer hormonal therapy More than 4 weeks since prior anticancer radiotherapy More than 4 weeks since prior anticancer surgery At least 4 weeks since other prior therapy for CLL or SLL and recovered